Compare FROG & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FROG | RGEN |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.2B |
| IPO Year | 2020 | N/A |
| Metric | FROG | RGEN |
|---|---|---|
| Price | $57.17 | $163.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 11 |
| Target Price | $66.72 | ★ $177.18 |
| AVG Volume (30 Days) | ★ 1.7M | 600.1K |
| Earning Date | 02-12-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $502,612,000.00 | ★ $707,890,000.00 |
| Revenue This Year | $24.88 | $17.86 |
| Revenue Next Year | $16.59 | $12.44 |
| P/E Ratio | ★ N/A | $5,247.54 |
| Revenue Growth | ★ 22.69 | 11.74 |
| 52 Week Low | $27.00 | $102.97 |
| 52 Week High | $70.43 | $182.52 |
| Indicator | FROG | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.15 | 48.28 |
| Support Level | $54.27 | $158.80 |
| Resistance Level | $59.40 | $172.51 |
| Average True Range (ATR) | 2.77 | 6.24 |
| MACD | -0.77 | -0.83 |
| Stochastic Oscillator | 26.95 | 25.84 |
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.